Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

105.71 +0.55 (+0.52%)

Streaming Delayed Price Updated: 10:10 AM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Volume	28,752
Open	104.80
Bid (Size)	105.52 (200)
Ask (Size)	106.09 (100)
Prev. Close	105.16
Today's Range	104.15 - 106.84
52wk Range	36.88 - 107.41
Shares Outstanding	38,297,975
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026

February 18, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Via The Motley Fool

Performance

YTD	+35.4%	+35.4%
1 Month	+12.1%	+12.1%
3 Month	+46.4%	+46.4%
6 Month	+47.2%	+47.2%
1 Year	+107.5%	+107.5%

More News

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Via The Motley Fool

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy ↗

February 14, 2026

Via Chartmill

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup ↗

February 10, 2026

Via Chartmill

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗

January 01, 2026

Via Chartmill

Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' ↗

December 08, 2025

Via Stocktwits

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

February 05, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Is Mirum Pharmaceuticals on a Strong Path to Profitability? ↗

January 31, 2026

Via The Motley Fool

Is Mirum Pharmaceuticals About to Soar in 2026? ↗

January 27, 2026

Via The Motley Fool

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

January 26, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)

January 13, 2026

Via PredictStreet

3 Top Growth Stocks to Buy in the First Half of 2026 ↗

January 13, 2026

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 ↗

January 12, 2026

Via The Motley Fool

Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum

January 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right ↗

January 04, 2026

Via The Motley Fool

Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now ↗

December 30, 2025

Via The Motley Fool

Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗

December 28, 2025

Via The Motley Fool

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

December 19, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

December 08, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?

Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.

What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?

Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?

The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market

What is the current price of Mirum Pharmaceuticals, Inc. - common stock?

The current price of Mirum Pharmaceuticals, Inc. - common stock is 105.71

When was Mirum Pharmaceuticals, Inc. - common stock last traded?

The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 02/23/26 10:10 AM ET

What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?

The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 4.05B

How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?

Mirum Pharmaceuticals, Inc. - common stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.